Development and validation of an analytical method using UPLC-MS/MS to quantify everolimus in dried blood spots in the oncology setting

Lotte M. Knapen; Yvo de Beer; Roger J. M. Bruggemann; Leo M. Stolk; Frank de Vries; Vivianne C. G. Tjan-Heijnen; Nielka P. van Erp; Sander Croes

doi:10.1016/j.jpba.2017.10.039

Development and validation of an analytical method using UPLC-MS/MS to quantify everolimus in dried blood spots in the oncology setting

Lotte M. Knapen, Yvo de Beer, Roger J. M. Bruggemann, Leo M. Stolk, Frank de Vries, Vivianne C. G. Tjan-Heijnen, Nielka P. van Erp, Sander Croes^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

12 Citations (Web of Science)

12 Downloads (Pure)

Original language	English
Pages (from-to)	106-113
Number of pages	8
Journal	Journal of Pharmaceutical and Biomedical Analysis
Volume	149
DOIs	https://doi.org/10.1016/j.jpba.2017.10.039
Publication status	Published - 5 Feb 2018

Keywords

Everolimus
Dried blood spot testing
Analytical method
Oncology
UPLC-MS/MS
Hematocrit
TANDEM MASS-SPECTROMETRY
RENAL-CELL CARCINOMA
NEUROENDOCRINE TUMORS
CYCLOSPORINE-A
SAMPLES
HEMATOCRIT
TACROLIMUS
SIROLIMUS
EXPOSURE
CANCER

Access to Document

10.1016/j.jpba.2017.10.039

Full textFinal published version, 1.65 MBLicence: Taverne

Cite this

Knapen, L. M., de Beer, Y., Bruggemann, R. J. M., Stolk, L. M., de Vries, F., Tjan-Heijnen, V. C. G., van Erp, N. P., & Croes, S. (2018). Development and validation of an analytical method using UPLC-MS/MS to quantify everolimus in dried blood spots in the oncology setting. Journal of Pharmaceutical and Biomedical Analysis, 149, 106-113. https://doi.org/10.1016/j.jpba.2017.10.039

Knapen, Lotte M. ; de Beer, Yvo ; Bruggemann, Roger J. M. ; Stolk, Leo M. ; de Vries, Frank ; Tjan-Heijnen, Vivianne C. G. ; van Erp, Nielka P. ; Croes, Sander. / Development and validation of an analytical method using UPLC-MS/MS to quantify everolimus in dried blood spots in the oncology setting. In: Journal of Pharmaceutical and Biomedical Analysis. 2018 ; Vol. 149. pp. 106-113.

@article{281d1732e68449ffa8f2f91fc79a05dd,

title = "Development and validation of an analytical method using UPLC-MS/MS to quantify everolimus in dried blood spots in the oncology setting",

keywords = "Everolimus, Dried blood spot testing, Analytical method, Oncology, UPLC-MS/MS, Hematocrit, TANDEM MASS-SPECTROMETRY, RENAL-CELL CARCINOMA, NEUROENDOCRINE TUMORS, CYCLOSPORINE-A, SAMPLES, HEMATOCRIT, TACROLIMUS, SIROLIMUS, EXPOSURE, CANCER",

author = "Knapen, {Lotte M.} and {de Beer}, Yvo and Bruggemann, {Roger J. M.} and Stolk, {Leo M.} and {de Vries}, Frank and Tjan-Heijnen, {Vivianne C. G.} and {van Erp}, {Nielka P.} and Sander Croes",

year = "2018",

month = feb,

day = "5",

doi = "10.1016/j.jpba.2017.10.039",

language = "English",

volume = "149",

pages = "106--113",

journal = "Journal of Pharmaceutical and Biomedical Analysis",

issn = "0731-7085",

publisher = "Elsevier",

}

Development and validation of an analytical method using UPLC-MS/MS to quantify everolimus in dried blood spots in the oncology setting. / Knapen, Lotte M.; de Beer, Yvo; Bruggemann, Roger J. M.; Stolk, Leo M.; de Vries, Frank ; Tjan-Heijnen, Vivianne C. G.; van Erp, Nielka P.; Croes, Sander.

In: Journal of Pharmaceutical and Biomedical Analysis, Vol. 149, 05.02.2018, p. 106-113.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Development and validation of an analytical method using UPLC-MS/MS to quantify everolimus in dried blood spots in the oncology setting

AU - Knapen, Lotte M.

AU - de Beer, Yvo

AU - Bruggemann, Roger J. M.

AU - Stolk, Leo M.

AU - de Vries, Frank

AU - Tjan-Heijnen, Vivianne C. G.

AU - van Erp, Nielka P.

AU - Croes, Sander

PY - 2018/2/5

Y1 - 2018/2/5

KW - Everolimus

KW - Dried blood spot testing

KW - Analytical method

KW - Oncology

KW - UPLC-MS/MS

KW - Hematocrit

KW - TANDEM MASS-SPECTROMETRY

KW - RENAL-CELL CARCINOMA

KW - NEUROENDOCRINE TUMORS

KW - CYCLOSPORINE-A

KW - SAMPLES

KW - HEMATOCRIT

KW - TACROLIMUS

KW - SIROLIMUS

KW - EXPOSURE

KW - CANCER

U2 - 10.1016/j.jpba.2017.10.039

DO - 10.1016/j.jpba.2017.10.039

M3 - Article

C2 - 29112898

VL - 149

SP - 106

EP - 113

JO - Journal of Pharmaceutical and Biomedical Analysis

JF - Journal of Pharmaceutical and Biomedical Analysis

SN - 0731-7085

ER -